Welcome to our dedicated page for Transmedics Group news (Ticker: TMDX), a resource for investors and traders seeking the latest updates and insights on Transmedics Group stock.
TransMedics Group, Inc. (Nasdaq: TMDX) is a medical technology company that focuses on transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure. News about TransMedics often centers on its Organ Care System (OCS) warm perfusion platform, the National OCS Program (NOP), and initiatives aimed at increasing donor organ utilization.
Investors and healthcare professionals following TransMedics news can expect updates on financial results, including quarterly earnings announcements and related conference calls, as reflected in the company’s regular press releases and Form 8-K filings. Coverage also includes participation in major healthcare and investor conferences, where management presents the company’s strategy and discusses its transplant-focused technologies and services.
Another key news theme is TransMedics’ expansion of its logistics and service infrastructure. The company has disclosed the acquisition of fixed-wing aircraft for its National OCS Program and has announced a strategic collaboration with Mercedes-Benz Group AG to launch a dedicated organ transplantation ground transportation network in Italy using Mercedes-Benz V-Class vehicles. These developments are presented as part of a broader effort to build an integrated air and ground logistics network around the OCS platform.
TransMedics also issues news related to corporate growth, such as inducement equity grants under Nasdaq Listing Rule 5635(c)(4) and plans for a new global headquarters and integrated campus in Somerville, Massachusetts. For readers tracking TMDX, this news feed provides a centralized view of operational updates, regulatory and financial disclosures referenced in press releases, and developments in the company’s organ transplant technologies and services.
TransMedics Group, Inc. (Nasdaq: TMDX), a leader in organ transplant technology, will announce its first-quarter 2022 financial results on May 3, 2022, after market close. A conference call to discuss these results will take place at 5:00 p.m. ET. Investors can access the call by dialing (844) 200-6205 domestically or (929) 526-1599 internationally, using Conference ID: 215877. The company aims to enhance organ preservation and assessment for transplants, addressing vital needs in heart, lung, and liver failure treatments.
TransMedics Group announces the presentation of new clinical data from its OCS™ Heart and Lung trials at the ISHLT 2022 Annual Meeting, scheduled for April 27-30, 2022, in Boston, MA. Key presentations include long-term results from the OCS DCD Heart trial and the OCS Lung EXPAND trial. These findings may significantly impact organ transplant therapy for patients with end-stage organ failure. TransMedics is set to host a symposium featuring global transplant leaders discussing their experiences with the OCS technology.
TransMedics Group, Inc. (Nasdaq: TMDX) will present virtually at the Oppenheimer 32nd Annual Healthcare Conference on March 16, 2022, at 3:20 p.m. EST. The company is at the forefront of improving organ transplant therapy for patients with end-stage heart, lung, and liver failure. A live and archived webcast of the presentation will be available on their Investors section. TransMedics specializes in portable extracorporeal warm perfusion and assessment of donor organs, enhancing organ viability and increasing usage rates.
TransMedics Group, Inc. (TMDX) announced on February 22, 2022, that it granted non-qualified stock options for 158,500 shares to eight new employees as an inducement to join the company. These options have an exercise price of $13.28, matching the Nasdaq closing price on the grant date. The options will vest 25% after one year, with the remainder vesting monthly over the next three years. The move aims to enhance employee retention as part of the company's growth strategy in organ transplant therapy, focusing on better organ quality and utilization.
TransMedics Group, Inc. (TMDX) reported strong financial results for 2021. Net revenue reached $9.7 million in Q4 2021, up 27% year-over-year. Full-year revenue increased 18% to $30.3 million. The company launched OCS™ Heart and OCS™ Liver in the U.S., significantly contributing to revenue growth. However, net loss widened to $12.7 million for Q4 and $44.2 million for the year. The gross margin improved to 72% in Q4 and 70% for the year. For 2022, TransMedics projects revenue between $49 million and $55 million, indicating potential growth of 62% to 82%.
TransMedics Group (Nasdaq: TMDX) will present at the Cowen 42nd Annual Healthcare Conference on March 9, 2022, at 9:50 a.m. EST. The executive team's presentation aims to highlight advancements in organ transplant therapy, particularly for patients experiencing end-stage lung, heart, and liver failure. TransMedics is a leader in portable warm perfusion technology, focusing on improving organ quality and viability assessment prior to transplantation.
Investors can access a live and archived webcast of the presentation on the TransMedics website.
TransMedics Group, Inc. (Nasdaq: TMDX) will announce its fourth quarter and full year 2021 financial results on February 23, 2022, after market close. A conference call to discuss the results will take place at 4:30 p.m. ET. The company specializes in portable extracorporeal warm perfusion for organ transplants, aiming to enhance organ availability for patients with end-stage conditions. Interested investors can access the call via phone or through a live webcast available on their website.
TransMedics Group, Inc. (Nasdaq: TMDX) announced on January 5, 2022, the publication of results from the OCS™ Liver PROTECT Trial in JAMA Surgery. The trial, which involved 300 participants, demonstrated significant improvements in short-term and mid-term clinical outcomes for liver transplants using the OCS™ Liver System. Key findings include a 41% reduction in early allograft dysfunction (EAD) and a higher utilization of livers from cardiac death donors. CEO Waleed Hassanein emphasized that these results could expand the donor pool and improve patient outcomes.
TransMedics Group, a leader in organ transplant technology, will present at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022, at 7:30 a.m. EST. The virtual event aims to showcase the company's advancements in portable warm perfusion and assessment of donor organs for transplantation. Founded to enhance organ availability and quality, TransMedics is dedicated to addressing the needs of patients with end-stage heart, lung, and liver failure. Interested parties can access the presentation live and archived on the TransMedics website.
TransMedics Group, Inc. (TMDX) announced the grant of non-qualified stock options for 240,500 shares of its common stock to eleven employees on November 5, 2021. The options, aimed at incentivizing new hires, were approved by the Compensation Committee and adhere to Nasdaq Listing Rule 5635(c)(4). Each option has a ten-year term with an exercise price of $31.49, the stock's closing price on the grant date. Vesting occurs at 25% after one year and monthly thereafter over three years, contingent on continued employment.